Latest Competition News

Megaport has posted a 37% jump in FY26 revenue to $312 million, driven by strategic acquisitions and a broadening platform across compute, network, and storage. The company raised over $1 billion to fund AI-focused contracts and infrastructure growth.

Maas Group Holdings posted a record FY26 with underlying EBITDA up 37% to $300.3 million, driven by electrical manufacturing growth. The $1.7 billion sale of its Construction Materials division to Heidelberg Materials is set to reshape its capital allocation and growth strategy.

Westgold Resources reports a 41% jump in gold Ore Reserves to 4.1 million ounces with a 15% grade uplift, achieved at a notably low reserve addition cost of $27 per ounce. The company plans to invest up to $75 million in exploration drilling in FY27 to sustain this growth trajectory.

Brambles Limited posted a 6% rise in sales revenue to US$7.04 billion for FY26, navigating US repair bottlenecks with decisive investments and reaffirming growth targets for FY27 and beyond.

Medibank Private Limited reported a 27.5% jump in net profit after tax to $638.7 million for FY26, driven by steady health insurance growth and a 31.3% surge in its Medibank Health segment. The company declared a fully franked final dividend of 10.9 cents per share and updated its Net Zero emissions strategy.

Spark New Zealand’s FY26 results highlight a return to mobile service revenue growth, a significant gain from the sale of its data centre business, and a strategic review of its Digital Services division.

H2G Limited trims its half-year loss by a third while advancing sodium-ion battery production and securing a $4.5 million sales pipeline. Strategic partnerships and government certification efforts aim to boost market adoption.

SCX.ai Holdings Limited is set to raise $40 million through a fully underwritten IPO at $0.30 per share, aiming to scale its sovereign AI inferencing platform built on ASIC hardware within Australian data centres. The company targets the fast-growing AI IaaS market with a focus on secure, low-latency AI workloads.

Percheron Therapeutics reduced its FY2026 loss to $4.79 million as it prepares to launch a pivotal phase II trial for its immuno-oncology drug HMBD-002, while managing a CEO transition and tightening cash reserves.

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

Recce Pharmaceuticals has secured ethics approval to add an active-controlled arm to its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, enabling head-to-head comparison against existing antibiotics.

ADX Energy has lodged applications for two offshore gas exploration permits adjacent to its existing Sicily Channel licence, aiming to extend its footprint in a geologically promising biogenic gas play.